EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer

Angela Yee, Jim Smith, Rajiv Kumar, Akash Sali, Euan J Rodger, Aniruddha Chatterjee

Cancer and Metastasis Reviews · 23.07.2026 · 45 (3)

DOI: 10.1007/s10555-026-10357-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, online erschienen am 23.07.2026. Verfasst von Angela Yee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, Faculty of Medicine, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Precision Medicine, Early Detection of Cancer. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Otago.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is the second-highest cause of cancer-related incidence and the fifth-highest cause of cancer mortality in males. Prostate cancer is a heterogeneous disease with a wide spectrum of clinical behaviour, ranging from indolent to highly aggressive. Molecular approaches, such as genomic testing, can augment existing clinical risk stratifications and tailor management to the individual. Genomic tests that sample biopsy or surgical tissue can provide a molecular risk assessment and identify actionable therapy targets. Liquid biopsy, while still emerging, may provide a non-invasive alternative to tissue tests and enable longitudinal monitoring of tumour status. We first discuss the molecular landscape of prostate cancer, before providing a detailed overview of the molecular approaches available for early detection and prognostication. Furthermore, methodological considerations and barriers towards clinical implementation for these tests are discussed, highlighting areas of future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorPrecision MedicineEarly Detection of CancerHumansMalePrognosisLiquid Biopsy

Stichwörter der Autor:innen

BiomarkersGenomic testingLiquid biopsyNext-generation sequencingPrecision medicineProstate cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Molecular Medicine, Faculty of Medicine, University of Otago, Dunedin, New Zealand.
  • Department of General Surgery, Dunedin Hospital, Te Whatu Ora Health NZ - Southern, Dunedin, New Zealand.
  • Department of Medicine, Faculty of Medicine, University of Otago, Dunedin, New Zealand.
  • Department of Pathology and Molecular Medicine, Faculty of Medicine, University of Otago, Dunedin, New Zealand. aniruddha.chatterjee@otago.ac.nz.
  • Honorary Professor, SoHST, UPES University, Dehradun, India. aniruddha.chatterjee@otago.ac.nz.

Förderung

  • University of Otago

Zitieren

APA

Yee, A., Smith, J., Kumar, R., Sali, A., Rodger, E. J., & Chatterjee, A. (2026). Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer. Cancer and Metastasis Reviews, 45(3). https://doi.org/10.1007/s10555-026-10357-8

Vancouver

Yee A, Smith J, Kumar R, Sali A, Rodger EJ, Chatterjee A. Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer. Cancer and Metastasis Reviews. 2026;45(3). doi:10.1007/s10555-026-10357-8

BibTeX
@article{Yee2026,
  author = {Yee, Angela and Smith, Jim and Kumar, Rajiv and Sali, Akash and Rodger, Euan J and Chatterjee, Aniruddha},
  title = {Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer},
  journal = {Cancer and Metastasis Reviews},
  year = {2026},
  volume = {45},
  number = {3},
  doi = {10.1007/s10555-026-10357-8}
}
Kostenlos starten →